AIM ImmunoTech

Hemispherx Biopharma is a small American pharmaceutical company that produces the drug Ampligen. Corporate headquarters are in Philadelphia, PA and the manufacturing and research facility is in New Brunswick, NJ. In addition to Ampligen, Hemispherx produces Alferon N Injection® and Alferon® LDO (Low Dose Oral). To date, only Alferon N Injection® has FDA approval. Ampligen and Alferon® LDO are not FDA-approved and are considered experimental.

In Feb 2016, Dr. William Carter, then Chairman and CEO, was terminated by the board of directors of Hermispherx Biopharma, who cited that part of the reason was a strong financial austerity plan. William M. Mitchell, M.D., Ph.D. was promoted in house as his replacement.

In June 2016, the law suit was resolved between Dr. Carter and Hemispherx regarding the wrongful termination claim. As part of the settlement, the intellectual property rights, including the patent for Ampligen and Alferon, are irrevocably assigned to to Hemispherx.

Management

 * Thomas K. Equels, M.S., J.D. - Executive Vice Chairman, Chief Executive Officer, President, Secretary & General Counsel
 * Adam Pascale, CPA - Chief Financial Officer
 * David R. Strayer, M.D. - Chief Scientific & Medical Officer
 * Wayne Springate - Senior Vice President of Operations

Board of Directors

 * William M. Mitchell, M.D., Ph.D. - Chairman of the Board
 * Thomas K. Equels, M.S., J.D. - Executive Vice Chairman, Chief Executive Officer, President, Secretary, & General Counsel
 * Peter W. Rodino III, Esq.- Lead Director

Marketing History

 * 2016, Hemispherx Biopharma announced that it has received approval of its New Drug Application (NDA) from Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica (ANMAT) for commercial sale of rintatolimod (U.S. tradename: Ampligen®) in the Argentine Republic for the treatment of severe myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
 * 2015, Hemispherx Biopharma partnered with a European company, myTomorrows, to bring Ampligen to the EU and Turkey through an Early Access Program for experimental drugs.
 * 2015, Hemispherx Biopharma executed an agreement with Emerge Health Pty Ltd. ("Emerge") to seek approval of Ampligen for Chronic Fatigue Syndrome in Australia and New Zealand and to commence distribution of Ampligen in both countries on a named-patient basis, where deemed appropriate.
 * 2004, Fujisawa Deutschland GmbH, a subsidiary of Fujisawa Pharmaceutical Co., entered into an option agreement with Hemispherx Biopharma with the intent of becoming a distributor for Ampligen for the potential treatment of chronic fatigue syndrome in Germany, Switzerland and Austria.
 * 2003, Hemispherx Biopharma Inc. entered into an agreement with Guangdong Medicine Group Corporation to organise clinical trials, marketing, sales and distribution for both of its lead compounds, Ampligen and Alferon N in the People's Republic of China
 * 2002, Esteve and Hemispherx Biopharma entered into a collaborative agreement under which Esteve will be the sole distributor of Ampligen in Spain, Portugal and Andorra for the treatment of chronic fatigue syndrome.
 * 2001, Hemispherx Biopharma announced that it was initiating phase II/III trials of Ampligen in the treatment of late-stage, multidrug-resistant strains of HIV in the European Union.
 * 2000, Crystaal Corporation (now Biovail Pharmaceuticals Canada) acquired exclusive marketing rights to Ampligen in Canada, where it submitted an NDA for the agent for the treatment of chronic fatigue syndrome.

Online presence

 * Website
 * SEC filings - Hemispherx Biompharma

Talks and interviews

 * 2016, Small Cap Nation - ME/CFS (Updated) (Thomas Equels)

Learn more

 * Wikipedia - Hemispherx Biopharma
 * Wikipedia - Rintatolimod
 * http://simmaronresearch.com/2016/05/hemispherx-ampligen-approval-chronic-fatigue-syndrome-top-priority/
 * 2016, Hemispherx Biopharma (HEB) Comments on Recent Meeting with NIH for ME/CFS Research Advancement (see also NIH Post-Infectious ME/CFS Study)
 * 2016, Ampligen Co-Inventor / Head of Hemispherx Biopharma Fired: Implications for ME/CFS Drug Unclear
 * 2014, Investor's post about HEB's rocky history